Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).

被引：0
|
作者：
Martini, Dylan J.
Shabto, Julie M.
Liu, Yuan
Carthon, Bradley Curtis
Speak, Alexandra
Hitron, Elise
Russler, Greta
Caulfield, Sarah
Ogan, Kenneth
Harris, Wayne
Master, Viraj A.
Kucuk, Omer
Bilen, Mehmet Asim
机构：
[1] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA
[2] Emory Univ, Dept Biostat, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Bioinformat, Atlanta, GA 30322 USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Emory Univ, Sch Med, Dept Pharmaceut Serv, Atlanta, GA USA
[6] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.585
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
585
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Master, Viraj A.
    Kucuk, Omer
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Master, Viraj A.
    Kucuk, Omer
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Cerbone, L.
    Di Nunno, V.
    Carril, L.
    Benchimol-Zouari, A.
    Flippot, R.
    Silva, C. Alves Costa
    Colomba-Blameble, E.
    Guida, A.
    Derosa, L.
    Escudier, B.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S577 - S577
  • [5] Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.
    Keeler, Molika Emmeline
    Kessler, Elizabeth Riley
    Bernard, Brandon
    Weisdack, Sarah
    Breaker, Kathryn M.
    Wold, Mali
    Ertz, Donna
    Weitzenkamp, David
    Flaig, Thomas W.
    Lam, Elaine Tat
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Clinical outcomes in metastatic renal cell carcinoma (mRCC) treated with combination of nivolumab and cabozantinib (nivo-cabo) in the salvage setting.
    Ravindranathan, Deepak
    Liu, Yuan
    Martini, Dylan J.
    Nazha, Bassel
    Brown, Jacqueline T.
    Russler, Greta
    Yantorni, Lauren Beth
    Caulfield, Sarah
    Master, Viraj A.
    Carthon, Bradley Curtis
    Kucuk, Omer
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Exposure toxicity and response relationship of cabozantinib (CABO) in patients with metastatic renal cell carcinoma (mRCC).
    Xu-Vuillard, Alexandre
    Jouinot, Anne
    Pudlarz, Thomas
    Blanchet, Benoit
    Huillard, Olivier
    Joly, Charlotte
    Tournigand, Christophe
    Oudard, Stephane
    Medioni, Jacques
    Vano, Yann-Alexandre
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [8] Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)
    Verzoni, E.
    Ferro, S.
    Procopio, G.
    Cova, A.
    Ratta, R.
    Raimondi, A.
    Sepe, P.
    Squarcina, P.
    Lalli, L.
    Huber, V.
    Rinchai, D.
    Bedognetti, D.
    Rivoltini, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib
    Golshayan, A. R.
    Elson, P.
    Wood, L. S.
    Garcia, J. A.
    Dreicer, R.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C)
    Kline, Meredith R.
    Martini, Dylan J.
    Liu, Yuan
    Shabto, Julie M.
    Carthon, Bradley Curtis
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Yantorni, Lauren Beth
    Harris, Wayne
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345